Tirzepatide for Treatment of CCCA

What Was Tested

In this phase 2 trial, researchers set out to test Tirzepatide.

The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults.

Participants will: * Inject tirzepatide once a week for 12 months. * Visit the clinic for scalp examinations, photographs, and other health assessments. * Have scalp biopsies at the beginning of the study and after 6 months of treatment. * Have blood tests and other safety monitoring during the study.

It had 1 arm (groups): Tirzepatide Treatment (experimental).

The registry classes the interventions as drug.

Who Took Part

20 planned participants were the target.

It was open to people of any sex aged from 18 years up to 80 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 18 to 80 years. Clinical and/or biopsy-confirmed diagnosis of central centrifugal cicatricial alopecia (CCCA). Active CCCA, defined as a C-CAT disease activity score greater than 1. No treatment for CCCA during the 6 weeks before enrollment. Able and willing to complete the study and follow all study procedures.

The full record lists 6 inclusion and 21 exclusion criteria; among the exclusions: currently taking an oral or systemic blood glucose-lowering medication; currently taking another medication for weight loss; homeostatic model assessment for insulin resistance (homa-ir) score below 2.

How the Study Was Run

The set-up was single-group and open-label.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-09-15 with completion listed for 2028-05-25.

It ran at 2 sites in United States (2).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Change in Central Centrifugal Cicatricial Alopecia Clinical Activity Tool Score (time frame: Baseline, 3 months, 6 months). Change in Scalp Gene-Expression Profiles (time frame: Baseline, 6 months).

It also tracked 2 secondary outcomes, for example Change in Central Hair Loss Grade and Physician Global Assessment of Change in Hair Loss.

What This Means in Plain Language

Put simply, this is a phase 2 trial of Tirzepatide in 20 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.